RxDoctor Payments Data

Colleen McMahon

Psychiatric/Mental Health · Diamondhead, MSNPI 1922559012

Payments from drug & device makers

$2,121in general payments, 2019–2025

Across 133 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$360
  • Corium, LLC$103
  • Vanda Pharmaceuticals Inc.$59
  • Supernus Pharmaceuticals, Inc.$32
  • E.r. Squibb & Sons, L.L.C.$27
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$2,09499%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,121 in reported general payments places this provider in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$18,190
Medicare patients
73
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl168$246,442
Invega SustennaPaliperidone Palmitate35$91,796
Chlorpromazine Hcl152$85,828
Abilify MaintenaAripiprazole13$36,851
CaplytaLumateperone Tosylate17$26,942
VivitrolNaltrexone Microspheres12$19,747
TrintellixVortioxetine Hydrobromide29$17,206
Asenapine Maleate48$12,117
Lisdexamfetamine Dimesylate42$11,270
Aripiprazole252$10,913
Oxcarbazepine329$10,788
Olanzapine412$9,107
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine283$8,825
Divalproex Sodium ErDivalproex Sodium147$8,692
Quetiapine Fumarate500$7,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,459$246,442168 claims
Johnson & JohnsonInvega Sustenna$15$91,79635 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$360$26,94217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Diamondhead

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →